Molecular markers in colorectal cancer:: genetic bases for a customised treatment

被引:10
作者
Casado, E. [1 ]
De Castro, J. [1 ]
Belda-Iniesta, C. [1 ]
Cejas, P. [1 ]
Feliu, J. [1 ]
Sereno, M. [1 ]
Gonzalez-Baron, M. [1 ]
机构
[1] Univ Autonoma Madrid, Translat Oncol Unit, Dept Med Oncol, Hosp Univ La Paz,CSIC, Madrid, Spain
关键词
colorectal cancer; molecular markers; prognosis; prediction; therapeutic targets; gene profiling;
D O I
10.1007/s12094-007-0102-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Colorectal cancer (CRC) is the second leading cause of cancer death in Western countries. CRC treatment is based on the employment of three chemotherapeutic drugs, including 5-fluorouracil, oxaliplatin and irinotecan, and the use of recently incorporated targeted agents directed to vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR). The approval of these biologicals and of others to come holds great promise for the improvement of patient outcome. The molecular bases for this lethal disease have been extensively investigated, laying the foundations for a rational and customised treatment approach, expanding the therapeutic index of current drugs and easing the incorporation of new molecules. Individual markers have been mainly investigated based on drug targets and metabolism. Also, the increasing availability of high-throughput technologies has prompted the opportunity for blind studies capable of screening new markers and of identifying the specific oncogenic pathways responsible for drug resistance in a given patient. An updated review of the field is presented in this article.
引用
收藏
页码:549 / 554
页数:6
相关论文
共 50 条
  • [1] Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer:: A national cancer institute-national surgical adjuvant breast and bowel project collaborative study
    Allegra, CJ
    Paik, S
    Colangelo, LH
    Parr, AL
    Kirsch, I
    Kim, G
    Klein, P
    Johnston, PG
    Wolmark, N
    Wieand, HS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) : 241 - 250
  • [2] Allegra CJ, 2003, NEW ENGL J MED, V349, P1774
  • [3] Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer:: a GERCOR study
    Andre, T.
    Tournigand, C.
    Mineur, L.
    Fellague-Chebra, R.
    Flesch, M.
    Mabro, M.
    Hebbar, M.
    Vinay, S. Postel
    Bidard, F. C.
    Louvet, C.
    de Gramont, A.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 (01) : 77 - 81
  • [4] Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines
    Arnould, S
    Hennebelle, I
    Canal, P
    Bugat, R
    Guichard, S
    [J]. EUROPEAN JOURNAL OF CANCER, 2003, 39 (01) : 112 - 119
  • [5] Colon cancer prognosis prediction by gene expression profiling
    Barrier, A
    Lemoine, A
    Boelle, PY
    Tse, C
    Brault, D
    Chiappini, F
    Breittschneider, J
    Lacaine, F
    Houry, S
    Huguier, M
    Van der Laan, MJ
    Speed, T
    Debuire, B
    Flahault, A
    Dudoit, S
    [J]. ONCOGENE, 2005, 24 (40) : 6155 - 6164
  • [6] Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters
    Bertucci, F
    Salas, S
    Eysteries, S
    Nasser, V
    Finetti, P
    Ginestier, C
    Charafe-Jauffret, E
    Loriod, B
    Bachelart, L
    Montfort, J
    Victorero, G
    Viret, F
    Ollendorff, V
    Fert, V
    Giovaninni, M
    Delpero, JR
    Nguyen, C
    Viens, P
    Monges, G
    Birnbaum, D
    Houlgatte, R
    [J]. ONCOGENE, 2004, 23 (07) : 1377 - 1391
  • [7] Oncogenic kinase signalling
    Blume-Jensen, P
    Hunter, T
    [J]. NATURE, 2001, 411 (6835) : 355 - 365
  • [8] Disruption of p53 in human cancer cells alters the responses to therapeutic agents
    Bunz, F
    Hwang, PM
    Torrance, C
    Waldman, T
    Zhang, YG
    Dillehay, L
    Williams, J
    Lengauer, C
    Kinzler, KW
    Vogelstein, B
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (03) : 263 - 269
  • [9] Cancer biology - Signatures guide drug choice
    Downward, J
    [J]. NATURE, 2006, 439 (7074) : 274 - 275
  • [10] Thymidylate synthase expression in colorectal cancer:: A prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy
    Edler, D
    Glimelius, B
    Hallström, M
    Jakobsen, A
    Johnston, PG
    Magnusson, I
    Ragnhammar, P
    Blomgren, H
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (07) : 1721 - 1728